Lancet Respiratory Medicine

Article	Citations
Savolitinib in NSCLC: progress in the MET exon 14 journey	968
Thoracentesis: an old story and some new sources	589
Concerns regarding a suggested long COVID paradigm – Authors' reply	484
Rituximab for connective tissue disease-associated interstitial lung disease	372
Broad protection from SARS-CoV-2 variants without antigen matching	301
The burden of tuberculosis in Libya	300
Why has the incidence of tuberculosis not reduced in London during the COVID-19 pandemic?	246
European Respiratory Society International Congress 2022	238
Correction to Lancet Respir Med 2019; 7: 745–56	236
US Senate committee investigates asthma inhaler prices	230
Major gaps in childhood pneumonia research priorities remain	220
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress	210
Opioids bring peace to patients with IPF cough	207
Correction to Lancet Respir Med 2024; 12: 129–40	203
Video laryngoscopy is not the nemesis of direct laryngoscopy	190
Postoperative CPAP after major abdominal surgery	187
Impact of Myanmar's earthquake on respiratory health	186
Predicted bodyweight—a misleading metric for tidal volume titration?	184
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership	180
Concerns about PRISm	178
FLiRTing with danger as SARS-CoV-2 variants evolve	176
Predatory publishers appear in PubMed (and your inbox)	175
Australia bans engineered stone to prevent silicosis	173
Long COVID: systemic inflammation and obesity as therapeutic targets	170
Chronic obstructive pulmonary disease: 10 years of precision-guided success	168

The course of action for effective anti-cytokine treatment in COVID-19	164
Interstitial lung disease: a decade of progress and hope	162
Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop	160
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis	159
First results from the international paediatric bronchiectasis registry (Child-BEAR-Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cros	158
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials	156
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study	154
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial	150
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study	149
Eat or heat: fuel poverty and childhood respiratory health	148
GOLD report: 2022 update	147
Advancing precision medicine for acute respiratory distress syndrome	144
Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials	142
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis	142
Vaccination in the world's top athletes	138
Overcoming barriers to scaling up tuberculosis preventive treatment for household contacts	138
Correction to Lancet Respir Med 2025; 13: 244–55	138
Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): a multinational study of asthma cohorts	137
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta	135
Correction to Lancet Respir Med 2021; 9: 1275–87	135
Trump administration decimates worker health oversight	134
Chronic cough as a disease: implications for practice, research, and health care	131
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis	130
Correction to Lancet Respir Med 2022; 10: 972–84	128
Claudio Castanos—leader in cystic fibrosis care in Argentina	126
Sarcoidosis and fatigue: there is a useful cognitive treatment? – Authors' reply	126
Nasally delivered SARS-CoV-2 vaccines: future promise and challenges	123
Genetic associations and lung function in IPF: unexpected answers, persistent questions	120
US EPA signals renewed regulatory scrutiny of toxic air pollution	120
Priorities for NICE in health and social care	120
Solid and semi-solid perspectives in thoracic surgery	119
Awake prone positioning in COVID-19: is tummy time ready for prime time?	117
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis	116
Association of SARS-CoV-2 infection and persistence with long COVID	112
Extracorporeal cardiopulmonary resuscitation: not why, but how	112
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study	111
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial	110
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial	108
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study	107
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis	106
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO	105
Improving lifelong respiratory health after preterm birth	105
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing s	104
Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial	103
Nintedanib for treating progressive fibrosing interstitial lung diseases	103
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial	101
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co	100
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials	97
Unveiling a hidden phenotype of early tuberculosis	97
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub	97

Health effects from climate-driven events: lessons learnt	96
Choice overload for RSV prevention—how to form your opinion	95
Spirometry in female individuals – Authors' reply	95
Management after combined BPA and medical therapy in CTEPH: time for cardiopulmonary exercise testing	94
Pre-COPD: an evolving concept with practice potential	93
Clean air, climate targets, and respiratory health in Europe	90
Tackling tuberculosis: what lies beneath the surface?	89
Venus and Mars: chest wall deformity and thoracic disease	89
NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma	88
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO	87
Correction to Lancet Respir Med 2023; 11: 1064–74	87
COP27 Climate Change Conference: urgent action needed for Africa and the world	86
Underappreciated causes of obstructive lung disease	83
Liberal or restrictive transfusion for VV ECMO	80
Opioid use and sleep apnoea	80
Pooled testing for TB: revisiting a cost-saving innovation	79
Realignment of clinical research after the COVID-19 era	79
Trouble with promoting lung cancer screening in never-smokers	78
US lung cancer report suggests years of encouraging progress under threat from health agency cuts	78
Early-life respiratory syncytial virus disease and long-term respiratory health	77
Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trial	77
Unavailability of varenicline: a global tragedy for the fight against the tobacco epidemic	75
Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven ot	73
Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial	72
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials	71
The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study	70
Developments and priorities in bronchiectasis research	69
Prevalence of sleep-disordered breathing in an African general population: The Benin Society and Sleep (BeSAS) study	67
COPD: a complex, multifactorial, but preventable disease?	66
Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis	66
Collateral caring	65
The recent explosion in snortable energy powder consumption	64
SIMPLIFYing cystic fibrosis treatment in a post-modulator era	64
Treating acute respiratory illness: the need to be proactive	64
Wildfires in southern California: concerns for lung health	64
Combined SHP2 and KRASG12C inhibitor therapy in patients with non-small-cell lung cancer	63
Society of Critical Care Medicine Critical Care Congress 2023	62
Managing tuberculosis before the onset of symptoms	62
COVID-19—an infectious disease in the top five causes of death in Australia	61
Time-dependent bias when analysing COVID-19-associated pulmonary aspergillosis – Authors' reply	57
Correction to Lancet Respir Med 2022; published online Feb 25. https://doi.org/10.1016/S2213-2600(22)00045-5	56
E-cigarette company tactics in sports advertising	56
Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomised controlled phase 4 trial	55
Breathing barriers: bridging lung health, research, and awareness	55
Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement	55
Pioneering a paradigm shift in asthma management: remission as a treatment goal	55
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial	54
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial	54
Home monitoring in interstitial lung diseases	54
Beyond the ventilator: rethinking daily evaluation of respiratory drive and effort	54
The effect of inhaled hypertonic saline on lung structure in children aged 3–6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial	54
Moving forward in IPF: lessons learned from clinical trials	52
Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis	52
Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from tw	52
Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial	52
Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	52
Core outcome measurement instruments for use in clinical and research settings for adults with post-COVID-19 condition: an international Delphi consensus study	52
Rise in group A streptococcal infections in England	51
Continuing ECMO with no possible transition to recovery or transplant	51
Waning immunity to SARS-CoV-2: implications for vaccine booster strategies	50
The importance of post-tuberculosis morbidity in high-income countries	50
Common and rare variants and survival in idiopathic pulmonary fibrosis	50
Sanjay Ramakrishnan—several lucky turns to arrive at COPD	49
Trial emulation with observational data in cystic fibrosis	49
What is adequate preoxygenation? – Authors' reply	49
Cardiac and vascular serious adverse events following tixagevimab–cilgavimab	49
NUTRIREA-3: where to next?	49
Tackling the global burden of lung disease through prevention and early diagnosis	48
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicent	48
Correction to Lancet Respir Med 2025; 13: 800–08	48
Remission in chronic cough: an achievable target?	47
EVEREST and the eosinophil paradox – Authors' reply	47
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and	47
Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multi	47
Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia	46
Continued enteral nutrition until extubation compared with fasting before extubation in patients in the intensive care unit: an open-label, cluster-randomised, parallel-group, non-inferiority trial	46
General population-based lung function trajectories over the life course: an accelerated cohort study	46
Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies	45
Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study	45
ECMO: more than just a bridge over troubled waters?	44

Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial	44
Reflections 5 years on from the approval of ETI therapy	44
Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled c	44
Use of lung-cancer trends for global and public health priorities	44
Perioperative lung expansion and pulmonary outcomes after abdominal surgery	44
Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis	44
Community-acquired pneumonia: the best candidates for clarithromycin	43
Stubble: the Farmer's Bane	43
Changes in rates of prescriptions for inhaled corticosteroids during the COVID-19 pandemic	43
The upcoming influenza season and protection from vaccines	42
US Senate announces planned gun reforms after latest school shooting	42
Postoperative CPAP after major abdominal surgery – Authors' reply	42
Lifting the veil on humour and anaesthetics	41
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO – Authors' reply	41
Flavia Machado—a Latin American leader in sepsis	41
Guidelines might help reduce the burden of asthma in African children	41
Correction to Lancet Respir Med 2023; published online Feb 3. https://doi.org/10.1016/S2213-2600(22)00491-X	41
Neomi Shah—cracking the conundrum of sleep disorders	40
Patient in her 70s with COPD and asthma improving significantly since using monoclonal antibody dupilumab	39
European Lung Cancer Congress 2024	39
Surviving sepsis with multiple serious complications	39
Oral corticosteroids for acute preschool wheeze	39
Correction to Lancet Respir Med 2024; 12: 544–55	39
Fighting sepsis: still a long way to go	37
Ventilation during surgery: moving away from one-size-fits-all	37
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised,	37
Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts	37
Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study	37
Chronic respiratory disease in Indigenous peoples: a framework to address inequity and strengthen respiratory health and health care globally	36
Management of prematurity-associated lung disease from infancy through to adulthood	35
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial	35
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study	35
Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management	35
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial	35
Effect of non-invasive ventilation after extubation in critically ill patients with obesity in France: a multicentre, unblinded, pragmatic randomised clinical trial	34
International guideline recommendations and eligibility criteria for home oxygen therapy	34
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study	34
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled,	34
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomi	33
C-reactive protein-guided treatment in pneumonia: charting a personalised approach – Authors’ reply	33
The carbon footprint of inhaled medications in Australia	33
Correction to Lancet Respir Med 2025; 13: 318–26	33
Time to escalate quality assurance in small-cell lung cancer radiotherapy trials – Authors' reply	33
Correction Lancet Respir Med 2022; 10: 937–48	32
Convalescent plasma in outpatients with COVID-19	32
Concerns regarding a suggested long COVID paradigm	32
Discussions on VT4COVID	32
It is time to include real-world effectiveness data on medicinal product labels	32
Remdesivir saves lives. Were 3 years needed to learn that?	32
Air pollution, climate change, and lung health in Europe	31
Outcome predictors and patient progress following delivery in pregnant and postpartum patients with severe COVID-19 pneumonitis in intensive care units in Israel (OB-COVICU): a nationwide cohort study	31
The passage of Ireland's Human Tissue Act: challenges, consequences, and cross-border cooperation	30
Unseen collateral damage: tackling preventable morbidity and mortality in family members of ICU decedents	30
Home-based monitoring in chronic respiratory diseases: in search of Panacea	30
Preoxygenation strategies for intubation: a closer look at inclusion criteria and patient heterogeneity – Authors' reply	30
Lockdown as the mother of invention: disruptive technology in a disrupted time	29
Arrival of biosimilars in respiratory medicine: towards improved access to biologics for patients	29
Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random?	29
Tuberculosis prevalence: beyond the tip of the iceberg	29
Continued resuscitation at the scene versus early transport for refractory out-of-hospital cardiac arrest	29
Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial	28
High-dose rifampicin to treat tuberculosis infection: potential and pitfalls	28
SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys	28
Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): a randomised controlled trial	27
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 tria	27
How Glasgow's 1957 tuberculosis screening programme could help countries today	27
Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis	26
Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial	26
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomise	26
US EPA strengthens PM2·5 air pollution limits	26
Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome	26
European Respiratory Society International Congress 2024	25
Concerning the use of aminoglycosides in ventilator-associated pneumonia – Authors' reply	25
Confounding undermines inferences of preventive therapy effectiveness among subgroups of tuberculosis contacts	25
Living with spinal muscular atrophy while working in critical care	25
What is next for BCG revaccination to prevent tuberculosis?	24
Idiopathic inflammatory myopathies related lung disease in adults	24
Chronic obstructive pulmonary disease: new therapies and old needs	24
The future of paediatric acute respiratory distress syndrome	24
Effects of SARS-CoV-2 on prenatal lung growth assessed by fetal MRI	24
Opportunities and challenges of COPD tertiary prevention	24
Addressing the origins and health effects of small lungs	23
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study	23
Phenotypes of idiopathic pulmonary arterial hypertension	23
Correction to Lancet Respir Med 2022; 10: 327–36	23
Treatment strategy for EGFR mutated NSCLC	23
Volcanic eruption in Tonga and effects on respiratory health	23
Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort study	23
Navigating uncertainty: asthma biologics during pregnancy	23
Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials	22
Trouble with promoting lung cancer screening in never-smokers – Authors' reply	22
D-dimer thresholds in pulmonary embolism: avoiding one-size-fits-all	22
Tuberculosis, conflict, and displacement	22
The Wuhan lockdown	22
Supporting families with tuberculosis during COVID-19 in Khayelithsa, South Africa	22